Compare KALU & OGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | KALU | OGN |
|---|---|---|
| Founded | 1946 | 1923 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Metal Fabrications | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.9B | 1.5B |
| IPO Year | 2006 | 2020 |
| Metric | KALU | OGN |
|---|---|---|
| Price | $130.72 | $6.11 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 3 | 4 |
| Target Price | ★ $107.00 | $11.75 |
| AVG Volume (30 Days) | 166.3K | ★ 3.0M |
| Earning Date | 04-22-2026 | 04-30-2026 |
| Dividend Yield | ★ 2.56% | 1.34% |
| EPS Growth | ★ 135.89 | N/A |
| EPS | ★ 6.77 | 0.72 |
| Revenue | $1,585,900,000.00 | ★ $6,216,000,000.00 |
| Revenue This Year | $13.37 | $0.42 |
| Revenue Next Year | $2.62 | $1.67 |
| P/E Ratio | $17.83 | ★ $8.31 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $46.81 | $5.69 |
| 52 Week High | $150.00 | $14.70 |
| Indicator | KALU | OGN |
|---|---|---|
| Relative Strength Index (RSI) | 59.99 | 39.63 |
| Support Level | $116.89 | N/A |
| Resistance Level | $136.10 | $7.87 |
| Average True Range (ATR) | 5.10 | 0.24 |
| MACD | 1.43 | 0.03 |
| Stochastic Oscillator | 99.08 | 51.79 |
Kaiser Aluminum Corp specializes in the production of semi-fabricated specialty aluminum mill products, such as aluminum plate and sheet, bare and coated coil and extruded and drawn products, for the end market applications: Aero/HS Products; Packaging; GE Products; and Automotive Extrusions. Its products include fabricated aluminum mill products such as flat-rolled (plate, sheet, and coil), extruded (rod, bar, hollows, and shapes), drawn (rod, bar, pipe, tube and wire) and certain cast aluminum products. Geographically, the company generates majority of its revenue from the United States.
Organon & Cois a globalised healthcare company with a mission to deliver impactful medicines and solutions for a healthier every day. Its operations include the following product portfolios: Women's Health: Itbwomen's health portfolio of products is sold by prescription mainly in two therapeutic areas: contraception, with key brands such as Nexplanon, and fertility, with key brands such as Follistim. other women's health products include the Jada, which is intended to provide control and treatment of abnormal postpartum uterine bleeding or hemorrhage when conservative management is warranted. The General Medicines portfolio includes biosimilars and established brands. Companies' current biosimilars portfolio spans across immunology and oncology-related treatments.